- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00746031
Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids
Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids.
Fibroids are present in up to 80% of women of reproductive age. Associated heavy menstrual bleeding is often an indication for surgery. At present there are no long-term medical treatments for fibroids. There is an unmet need for a pharmacologic agent able to reduce excessive bleeding and other symptoms associated with increased uterine volume, which could prevent or significantly delay surgery without causing significant unwanted hypoestrogenic side effects and allow preservation of fertility.
The purpose of this study is to investigate and validate novel MR imaging as a non-invasive biomarker for monitoring responses to medical interventions aimed at reduction of excessive menstrual bleeding and decrease in uterine/ fibroid volume. MR imaging is non-invasive, does not involve ionizing radiation and new techniques have the potential to resolve tissue detail to near cellular level.
The investigators are aiming to establish the feasibility and reproducibility of novel MR imaging techniques in the evaluation of treatment response in women with fibroids and to provide mechanistic information on whether the reduction in blood flow of uterine/fibroid vasculature in the shrinkage of fibroids is dependent upon subjects being hypoestrogenic.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Edinburgh, United Kingdom, EH16 4SA
- University of Edinburgh/ Royal Infirmary of Edinburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age>18 years
- Scheduled for hysterectomy with a fibroid uterus
- At least one intramural non-pedunculated, submucosal or subserous fibroid(>2cm) or multiple small fibroids (uterine volume>200cm3)
- Ability to understand and willingness to sign consent form
- Normal smear within 3 years
Exclusion criteria:
- Pregnant or lactating
- Contra indication to MRI
- Unable to tolerate supine position
- Diabetes and/or renal or hepatic impairment
- Contra indication to any of the study medications including gadolinium, MRI contrast
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: 3
|
|
Active Comparator: 1
GnRH analogue-Zoladex
|
3.6mg subcutaneous implant.
Monthly doses x 3.
|
Active Comparator: 2
GnRH antagonist plus GnRH analogue
|
3.6mg subcutaneous implant.
Monthly doses x 3.
Subcutaneous injection 3mg x3 over 7 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Uterine and fibroid volume
Time Frame: 2010
|
2010
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Uterine vascular perfusion, vasculature and extracellular matrix (ECM)content of fibroids.
Time Frame: 2010
|
2010
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: HILARY OD CRITCHLEY, MBChB;MD;FRCOG, University of Edinburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Connective Tissue Diseases
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Leiomyoma
- Myofibroma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Goserelin
- Cetrorelix
- Prolactin Release-Inhibiting Factors
Other Study ID Numbers
- REC number 08/MRE00/30
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leiomyoma
-
University of Sao PauloTerminated
-
Zagazig UniversityCompletedSubmucous Leiomyoma of Uterus
-
Eye & ENT Hospital of Fudan UniversityUnknownLaryngeal Leiomyoma | Probe-based Confocal Laser EndomicroscopyChina
-
Ain Shams UniversityRecruitingUterine LeiomyomaEgypt
-
Scitech Produtos Medicos LtdaCompletedUterine LeiomyomaBrazil
-
Seoul National University HospitalALPINION Medical SystemsCompleted
-
Universita di VeronaRecruiting
-
Sisli Hamidiye Etfal Training and Research HospitalCompleted
-
Loyola UniversityCompletedUterine Leiomyoma
-
Thunder Bay Regional Research InstituteWithdrawnUterine LeiomyomaCanada
Clinical Trials on GnRH analogue (Zoladex)
-
University Magna GraeciaCompleted
-
Sun Yat-sen UniversityNot yet recruiting
-
German Breast GroupPfizerCompletedMale Breast CancerGermany
-
University College, LondonRecruiting
-
Royal College of Surgeons, IrelandSteroid Metabolism Analysis Core, University of Birmingham; Institute of Systems...Not yet recruitingCardiovascular Diseases | Obesity | Diabetes | Metabolic Syndrome | Prostate Cancer | NAFLD | Metabolic Disturbance | Metabolic Disease | Hypogonadism, Male | Testosterone Deficiency | Androgen DeficiencyIreland
-
University Magna GraeciaCompletedEndometriosis | Pelvic Pain | Uterine Fibroids | Endometriosis of UterusItaly
-
Seattle Institute for Biomedical and Clinical ResearchUnited States Department of Defense; University of WashingtonActive, not recruitingMetastatic Prostate Cancer | Androgen Deprivation TherapyUnited States
-
Bakri ElsheikhGenentech, Inc.RecruitingSpinal Muscular AtrophyUnited States
-
University of Sao PauloUnknown
-
AstraZenecaWithdrawn